Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mindray Medical International

Related MR
UPDATE: Jefferies Assumes Coverage On Mindray Medical International Ltd. On Moderate Growth Prospects
Mindray Medical Misses on Q1 Earnings - Analyst Blog

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mindray Medical International (NYSE: MR), and raised its price target from $34.00 to $36.00.

Jefferies noted, “MR put up a mixed 3Q with a drastic slowdown in PMLS, a sequential stepback in the margin profile, but in-line non-GAAP EPS. Language regarding deterioration in developed markets, abrupt CEO change, and still unresolved supplier dispute leave lingering questions but overall growth profile still among upper tier.”

Mindray Medical International closed on Tuesday at $31.90.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (MR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free